Novozymes A/S (OTCMKTS:NVZMY) Short Interest Update

Novozymes A/S (OTCMKTS:NVZMY) saw a large drop in short interest in September. As of September 15th, there was short interest totaling 12,081 shares, a drop of 64.7% from the August 31st total of 34,196 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 39,198 shares, the short-interest ratio is presently 0.3 days.

Institutional Investors Weigh In On Novozymes A/S

An institutional investor recently raised its position in Novozymes A/S stock. Elefante Mark B raised its position in shares of Novozymes A/S (OTCMKTS:NVZMY) by 73.5% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,900 shares of the biotechnology company’s stock after buying an additional 2,500 shares during the period. Elefante Mark B’s holdings in Novozymes A/S were worth $371,000 at the end of the most recent reporting period. 0.03% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Zacks Research upgraded shares of Novozymes A/S from a “strong sell” rating to a “hold” rating in a report on Monday, June 8th. Two equities research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy”.

Novozymes A/S Trading Down 2.1%

Shares of OTCMKTS NVZMY traded down $1.38 during midday trading on Tuesday, reaching $63.45. The company had a trading volume of 19,447 shares, compared to its average volume of 63,510. The stock has a market cap of $26.30 billion, a PE ratio of 40.16, a price-to-earnings-growth ratio of 2.82 and a beta of 0.93. Novozymes A/S has a one year low of $49.90 and a one year high of $75.27. The firm’s fifty day moving average price is $66.64 and its 200-day moving average price is $62.19. The company has a quick ratio of 1.04, a current ratio of 1.74 and a debt-to-equity ratio of 0.25.

Novozymes A/S (OTCMKTS:NVZMY) last posted its quarterly earnings results on Thursday, August 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by ($0.16). Novozymes A/S had a return on equity of 6.54% and a net margin of 14.70%.The company had revenue of $1.30 billion for the quarter, compared to the consensus estimate of $1.27 billion. On average, equities research analysts anticipate that Novozymes A/S will post 2.51 earnings per share for the current year.

About Novozymes A/S

Novozymes A/S was a Danish biotechnology company specializing in biological solutions based on enzymes, microorganisms and related technologies. Its products were designed to help businesses improve manufacturing efficiency, reduce resource use and develop more sustainable alternatives to conventional chemical processes.

The company supplied enzyme and microbial products for a range of industries, including household care, food and beverages, agriculture, animal health, bioenergy and industrial manufacturing.